Use of Endostatin Peptides for the Treatment of Fibrosis

C-terminal endostatin polypeptides are disclosed herein. These polypeptides include or consist of at least at least 40 consecutive amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2 or SEQ ID NO: 13 with at most 5 amino acid substitutions, wherein the polypeptide has anti-fibrotic activity and wherein the polypeptide does not comprise amino acids 1-92 of SEQ ID NO: 2 or SEQ ID NO: 13. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung. Also disclosed are methods of decreasing lysyl oxidase (LOX) production in a cell or increasing matrix metalloproteinase production in a cell involving contacting the cells with the polypeptides.

WO 2,011,050,311


Type of Offer: Licensing

Next Patent »
« More Medical Patents

Share on      

CrowdSell Your Patent